- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07610057
R. Officinalis as Pulpotomy Agent in Permanent Teeth With Irreversible Pulpitis
Comparative Clinical and Radiographic Evaluation of Rosmarinus Officinalis Versus Mineral Trioxide Aggregate as Pulpotomy Medicament in Vital Mature Permanent Teeth With Irreversible Pulpitis
Study Overview
Status
Intervention / Treatment
Detailed Description
Traditionally, teeth with irreversible pulpitis have been treated either by root canal therapy or extraction, yet root canal treatment, although considered the gold standard, still presents limitations because it is technique-sensitive, invasive, time-consuming, and costly. To address these issues, more affordable and minimally invasive alternatives are being explored. With better understanding of the regenerative and healing abilities of inflamed pulp, along with the development of biologically active materials, vital pulp therapy is now increasingly viewed as a suitable alternative for managing irreversible pulpitis. Mineral trioxide aggregate is widely accepted as the current gold standard, but its drawbacks-including high cost, extended setting time and potential tooth discoloration-remain significant concerns. As a result, newer materials are being evaluated that are more cost-effective while avoiding these disadvantages.
One such material, Rosmarinus officinalis, has been used in vital pulp therapy of primary molars and has shown promising results. Despite the documented antimicrobial and anti-inflammatory properties of R. officinalis, its use as a pulpotomy agent in permanent teeth with irreversible pulpitis has not yet been investigated. This study aims to compare the outcomes of pulpotomy treatment using R. officinalis extract both clinically and radiographically versus MTA. This may help provide an alternative to RCT and a more economical option than MTA, while aiming for comparable effectiveness and addressing the limitations associated with MTA. Healthy young adults exhibiting signs and symptoms of irreversible pulpitis in at least one permanent posterior tooth, showing no periapical radiolucency in a periapical x-ray, along with the absence of swelling or sinus tract formation will be selected. Only the teeth with hemostasis achieved following the removal of coronal pulp will be included.
A randomized control trail will be conducted, wherein participants will be randomly assigned, using lottery method, to two groups, each consisting of 50 individuals of age 18-40 years of both sexes. After administration of anesthesia and isolation using a rubber dam, a sterile diamond round bur in a high-speed handpiece with water spray will used to remove enamel caries and carbide round bur in slow speed handpiece is used to remove dentinal caries. After the access opening, the coronal pulp will be removed up to the level of the canal orifice using a spoon excavator. After rinsing with sterile saline, hemostasis will be achieved by placing damp cotton soaked in saline. For group A, cotton will be dipped in R-officinalis extract, and placed over radicular pulp for 5 minutes and the pulp chamber will be sealed with a thick paste of aqueous R. officinalis extract with zinc oxide powder and for group B, white MTA will be prepared according to the manufacturer's instructions and placed in the pulp chamber compacted with a damp cotton pellet. Both will be restored with glass ionomer followed by direct composite. An immediate post-op periapical x-ray will be exposed. For clinical and radiographical evaluation patients will be recalled for follow-up at 1 week, 3 month and 6 months. Statistical analysis will be performed at the significance level of p= 0.05.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Zoha Nasir, BDS
- Phone Number: +923224056794
- Email: zohanasirsheikh@gmail.com
Study Locations
-
-
Punjab Province
-
Lahore, Punjab Province, Pakistan, 54000
- Punjab Dental Hospital, Lahore .
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria
- Healthy patients (ASA classification 1 and 2) of age range of 18-40 of both sexes would be included.
- Vital mature permanent posterior teeth with deep caries approaching the pulp as seen on periapical x-ray.
- Pain indicative of irreversible pulpitis (spontaneous pain or pain exacerbated by a cold stimulus which could last from a few seconds to hours), which a cold test could reproduce.
- Tooth will be selected on the basis of working diagnosis i.e. successful hemostasis within 5 minutes after removal of coronal pulp.
- Absence of clinical signs or symptoms suggesting a non-vital tooth such as tenderness to percussion or palpation, mobility, presence of abscess, soft tissue swelling or suppurating sinus.
- Absence of radiographic changes as; furcation or periapical pathology, internal or external root resorption or calcification in the canals.
- The tooth structure of selected teeth should be restorable after completion of the treatment
Exclusion Criteria:
- Patients with ASA classification 3, 4 ,5 and 6 would be
- Patients taking antibiotics within last 2 weeks.
- Teeth with pulp necrosis, cracked tooth, internal or external resorption, calcified canals, acute or chronic apical periodontitis with an associated sinus tract or periapical radiolucency.
- Periodontally compromised tooth.
- Uncooperative patients or failure to obtain authorization from patients.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: Control Group with MTA pulpotomy
Pulpotomy Medicaent in control group
|
MTA shall be mixed according to the manufacturer's instructions (PD SWISS).
After achieving a creamy mixture, MTA shall be delivered to the pulp chamber using an amalgam carrier to a 1-2mm thickness.
Using a moist pellet, it will be condensed gently over the exposed pulp stumps.
Once an initial set of MTA is achieved, the access cavity shall be restored with a glass ionomer cement and composite restoration.
|
|
Experimental: Intervention
R. officinalis as pulpotomy medicament
|
A sterile cotton pellet dipped and squeezed in 6.25% aqueous extract of R-officinalis will be placed over the radicular pulp for 5 minutes.
Then, the pulp chamber will be sealed with a thick paste aqueous extract of R. officinalis and zinc oxide powder.
The access cavity shall be restored with glass ionomer cement and a composite restoration.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Pain After Intervention, Tenderness to palpation, percussion , Swelling
Time Frame: Preop Post op after 1 week, 1month 3 month 6 month
|
The incidence and intensity of pain will be assessed postoperatively using the Visual Analogue scale. Pain intensity will be noted as no pain (0-4mm), mild pain (5-44), moderate pain (45-74mm) and severe pain (75-100mm) on a scale of 0-100mm |
Preop Post op after 1 week, 1month 3 month 6 month
|
|
Periapical status after intervention
Time Frame: Preop Post op 3 month 6 month
|
The periapical status will be assessed by using the periapical index [PAI] scoring system. Each tooth will be assigned to one of the PAI scores for the 5 categories within the scale. PAI less than or equal to 2 would be successful outcome.
|
Preop Post op 3 month 6 month
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- 60/24
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Irreversible Pulpitis
-
Tehran University of Medical SciencesActive, not recruitingSymptomatic Irreversible Pulpitis (SIP) | Symptomatic Irreversible Pulpitis With Apical PeridontitisIran
-
Cairo UniversityNot yet recruitingPulpitis - Reversible | Pulpitis - Irreversible
-
Mansoura UniversityCompletedIrreversible Pulpitis | Reversible PulpitisEgypt
-
Urooj FatimaNot yet recruitingSymptomatic Irreversible Pulpitis | Irreversible Pulpitis | Asymptomatic Irreversible PulpitisPakistan
-
Cukurova UniversityCompletedPulpitis - IrreversibleTurkey (Türkiye)
-
Jamia Millia IslamiaRecruiting
-
Cairo UniversityNot yet recruiting
-
Minia UniversityNot yet recruiting
-
Chulalongkorn UniversityNot yet recruiting
-
Sirawut Hiran-usChulalongkorn UniversityActive, not recruiting
Clinical Trials on MTA Pulpotomy
-
Necmettin Erbakan Universitynecmettin erbakan university Scientific Research Projects (BAP)Completed
-
Cairo UniversityUnknownSymptomatic Irreversible Pulpitis
-
University GhentCompleted
-
Cairo UniversityNot yet recruiting
-
Damascus UniversityCompleted
-
sherouk atef elsayedCairo UniversityNot yet recruiting
-
Jordan University of Science and TechnologyActive, not recruiting
-
Cumhuriyet UniversityCompletedSymptomatic Irreversible Pulpitis (SIP)Turkey (Türkiye)
-
University of Maryland, BaltimoreActive, not recruitingPulpotomy | Vital Pulp Therapies | Indirect Pulp CapUnited States